<DOC>
	<DOCNO>NCT00369252</DOCNO>
	<brief_summary>This phase I trial nimotuzumab conduct patient advanced incurable solid tumor . This dose-seeking study determine maximum tolerate recommend phase II dose nimotuzumab safely give patient advance and/or metastatic solid tumor .</brief_summary>
	<brief_title>Phase I Study Nimotuzumab Solid Tumours</brief_title>
	<detailed_description>This open-label , dose-escalating , phase I trial nimotuzumab patient advance incurable solid tumor . The objective study determine maximum tolerate dose ( MTD ) recommend phase II dose ( RP2D ) nimotuzumab give weekly schedule patient advance and/or metastatic solid tumor cancer . This study also examine safety , pharmacodynamics preliminary efficacy nimotuzumab patient population .</detailed_description>
	<criteria>Advanced and/or metastatic solid tumor , refractory standard curative therapy , curative therapy exists . Clinically radiologically document disease . Patients must measurable disease , define least one lesion accurately measure least one dimension ( long diameter record ) &gt; 20 mm conventional technique &gt; 10 mm spiral CT scan . Archival tumor specimen evaluable expression EGFR ( EGFR positivity requirement study entry ) . Patients must tumor lesion accessible biopsy correlative study . In case medical contraindication tumor biopsy , exception may make upon discussion Principal Investigators . Age &gt; 18 year . ECOG performance status 0,1,2 . Previous therapy : Previous chemotherapy , hormonal therapy , radiation and/or surgery permit certain restriction outline protocol . Hematology chemistry lab result within specification outline protocol . Willingness give write informed consent . Patients must accessible treatment followup . Protocol treatment begin within 2 work day patient registration . Pregnant lactating woman . Both men woman enrol study use adequate birth control measure throughout course study . History second malignancy diseasefree interval less two year ( except cervical cancer situ nonmelanomatous skin cancer ) . Untreated brain meningeal metastasis . Patients treat stable brain metastasis eligible provide radiologic evidence disease stabilisation least 3 month duration asymptomatic . Untreated and/or uncontrolled cardiovascular condition and/or symptomatic cardiac dysfunction . Active uncontrolled infection , serious illness medical condition would permit patient manage accord protocol . Prior therapy EGFR target therapy , include monoclonal antibody small molecule tyrosine kinase inhibitor . Allergy antibody . Concurrent treatment experimental drug anticancer therapy . Inability unwillingness give write , informed consent prior study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>Nimotuzumab</keyword>
	<keyword>TheraCIM</keyword>
	<keyword>H-R3</keyword>
	<keyword>Solid tumour</keyword>
	<keyword>EGFR</keyword>
	<keyword>Monoclonal antibody</keyword>
</DOC>